Reuters logo
BRIEF-Mirati announces advancement of opportunities with inhibitor programs
2017年11月13日 / 晚上9点55分 / 11 天前

BRIEF-Mirati announces advancement of opportunities with inhibitor programs

Nov 13 (Reuters) - Mirati Therapeutics Inc:

* Mirati Therapeutics announces advancement of first-in-class opportunities with sitravatinib and kras inhibitor programs

* Mirati Therapeutics - ‍“reprioritizing” development programs to capitalize on data and development opportunities in its sitravatinib and kras programs​

* Mirati Therapeutics - ‍reallocation of resources to support expansion of sitravatinib and kras programs, is expected to fund operations into late 2019​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below